Pyroptosis Machinery: Inflammasome Assembly, Caspase-1, and Gasdermin D Pore
Pyroptosis (pro-inflammatory lytic cell death; gasdermin family N-terminal pore; membrane permeabilisation → LDH/HMGB1/IL-1β/IL-18 release; distinct from apoptosis/necroptosis; key in: sepsis/SIRS, NLRP3-driven metabolic disease/NASH/ASCVD/gout/T2DM, AIM2-driven SLE/IBD, inflammatory lung/gut): Canonical inflammasome pathway (NLRP3 (2-signal model: Signal 1: TLR4/LPS/TNFα/IL-1β → NF-κB → NLRP3 mRNA ↑ + pro-IL-1β mRNA ↑ (transcriptional priming); Signal 2 (assembly/activation): ATP-P2X7 → K+ efflux; nigericin → K+ efflux; alum/uric acid crystals → lysosomal rupture; mtROS (mitochondrial ROS; TXNIP–NLRP3 interaction); AMPK ↓; palmitate/fatty acids)); NLRP3 (nucleotide-binding domain leucine-rich repeat pyrin domain containing 3; 1016 aa; PYD (pyrin domain; ASC interaction) + NBD/NACHT (ATPase; oligomerisation) + LRR (autoinhibition; ligand sensing); NLRP3 resting (D ring monomer; ADP-bound); activation: K+ efflux → NLRP3 decaging (NEK7 Lys378 kinase; NLRP3 LRR interaction; NEK7 K+-sensitive)); ASC (speck; PYD → NLRP3 PYD; CARD → procaspase-1 CARD → ASC filament → large perinuclear speck → procaspase-1 proximity-induced dimerisation → caspase-1 Cys285 active); caspase-1 substrates: (a) IL-1β (pro-IL-1β Asp116 → mature IL-1β 17 kDa; IL-18 Pro-Asp119 → mature IL-18); (b) gasdermin D (GSDMD; Asp275/Asp276 caspase-1/4/5/11 cleavage → GSDMD-N (N-terminal 1–275) + GSDMD-C (inhibitory); GSDMD-N: PI(4,5)P2/cardiolipin binding → oligomerisation → 10–16 nm pore → K+/Na+/Ca2+/IL-1β/IL-18 export + H2O entry → cell swelling → pyroptosis); Non-canonical (caspase-4/5/11): cytoplasmic LPS → caspase-4/5 (human)/11 (mouse) LRR-LPS direct binding → caspase activation → GSDMD cleavage → pyroptosis (IL-1β/IL-18-independent); also caspase-4/11 → NLRP3/caspase-1 secondary (canonical activation); AIM2 (absent in melanoma 2; cytoplasmic dsDNA; HIN domain; AIM2-ASC-caspase-1 → GSDMD; viral DNA/self-DNA/mtDNA); NLRP1 (thioredoxin-DPP9 interaction; anthrax LF protease; UV radiation); CARD8 (DPP8/9 sensor); Pyrin inflammasome (MEFV; Rho GTPase; familial Mediterranean fever).
Spirulina Mechanisms in Pyroptosis Modulation
NF-κB NLRP3/pro-IL-1β Priming Suppression
Signal 1 transcriptional priming (NLRP3 promoter NF-κB binding sites (−1200/−1150; −1070/−1020) → NF-κB p65-p50 → NLRP3 mRNA ↑ 5–10× (LPS; TNFα); pro-IL-1β promoter: NF-κB sites → pro-IL-1β mRNA ↑; pro-IL-18 partially NF-κB; NLRP3 protein basal undetectable in most unstimulated cells; only after NF-κB priming does NLRP3 accumulate to activatable levels; without priming: Signal 2 is insufficient for full NLRP3 activation; NEK7 expression: constitutive; not NF-κB regulated; AP-1 (c-Fos/c-Jun) also → NLRP3 priming at AP-1 sites): spirulina phycocyanin IKKβ Ser177/181 ↓ → NF-κB p65 nuclear ↓ → NLRP3 mRNA ↓ −30–50% (LPS-primed macrophages; spirulina pre-treatment 24h); pro-IL-1β mRNA ↓ −25–40%; additionally Nrf2 competes with p65 for CBP/p300 → NLRP3/pro-IL-1β transcription ↓; ERK (phycocyanin ↓ via RAS Cys118) → AP-1 ↓ → NLRP3 AP-1 sites ↓; net: priming suppression is the dominant spirulina anti-pyroptotic mechanism.
P2X7–K+ Efflux and mtROS NLRP3 Signal 2 Attenuation
NLRP3 activation signals (Signal 2 mechanisms: (A) K+ efflux: intracellular K+ ↓ <90 mM → NLRP3 decaging (NEK7 Lys378 conformational; NLRP3 oligomerisation); ATP-P2X7 (P2X7 → pannexin-1 → K+/Na+/Ca2+ flux → K+ efflux → NLRP3); (B) mtROS: mitochondrial dysfunction → O2•−/H2O2 → TXNIP (thioredoxin-interacting protein; dissociates from TRX under oxidative stress) → TXNIP-NLRP3 PYD interaction → NLRP3 activation; also mtROS → NLRP3 cardiolipin binding at mitochondrial surface; (C) Cholesterol crystals/lysosomal rupture: cathepsin B release → NLRP3 PYD + ASC speck; (D) AMPK ↓: AMPK inhibits NLRP3 via ULK1-mediated autophagy of mitochondria → reduces mtROS; also AMPK direct: AMPK → DRP1 S616 deactivation → mitochondrial fission ↓ → mtROS ↓): spirulina: (1) P2X7: NF-κB ↓ → P2X7 expression ↓ −15–25% (NF-κB site in P2X7 promoter; purinergic post covers this in detail); Mg2+ (spirulina ~80–150 mg/100g) → P2X7 Mg2+-inhibition; (2) mtROS: AMPK → mitophagy (PINK1/Parkin) → damaged mitochondria cleared → mtROS ↓ −20–30%; Nrf2 → SOD2/TRX2 → TXNIP-TRX2 association maintained (TRX reduced → binds TXNIP → TXNIP-NLRP3 dissociation ↓) → NLRP3 activation ↓ −15–25%.
GSDMD Cleavage and Pore Assembly Reduction
GSDMD regulation (caspase-1 Asp275/276 GSDMD cleavage: spirulina reduces upstream caspase-1 activation via (1) NLRP3 priming/activation ↓ (above) → ASC speck formation ↓ → procaspase-1 proximity ↓ → caspase-1 Cys285 ↓; (2) GSDMD-N pore: oxidative modification of GSDMD-N Cys191/Cys192 → altered GSDMD-N oligomerisation (H2O2 at high concentrations → GSDMD-N disulphide → inactive; paradox: ROS can inhibit GSDMD at very high concentration but promote NLRP3 activation at lower concentration); Nrf2 → GSH maintains GSDMD-N Cys in reduced form (active pore); BUT spirulina's dominant effect: NLRP3 ↓ → caspase-1 ↓ → GSDMD cleavage ↓ → overall pyroptosis ↓); non-canonical (caspase-4/5/11): LPS → cytoplasmic LPS → spirulina phycocyanin does not directly inhibit caspase-4/5/11 catalytic Cys; but NF-κB ↓ reduces LPS translocation (reduces LPS-induced cytokine storm which exacerbates caspase-4/11 priming); net: cleaved GSDMD-N ↓ −20–35% (canonical NLRP3; LPS+ATP model); IL-1β mature ↓ −25–40%; IL-18 mature ↓ −20–35%.
AIM2 and Nrf2-mtDNA Reduction
AIM2 inflammasome-spirulina (AIM2 (HIN domain; cytoplasmic dsDNA; mtDNA (released by MOMP/VDAC1) → AIM2; viral DNA (HSV/vaccinia); self-dsDNA in SLE/Aicardi-Goutières; AIM2-ASC-procaspase-1 → GSDMD → pyroptosis; AIM2 → caspase-1 → IL-1β/IL-18; AIM2 → caspase-3 (indirect; some models)): spirulina Nrf2-OGG1 → mtDNA 8-OHdG ↓ −20–35% → Trex1-resistant oxidised mtDNA ↓ → cytoplasmic dsDNA (AIM2 ligand) ↓ → AIM2 inflammasome assembly ↓ −15–25%; additionally cGAS-STING activated by same oxidised mtDNA (covered in previous post): spirulina Nrf2 provides dual protection (AIM2 + cGAS-STING); MOMP protection: AMPK → Bcl-2/Bcl-XL → BAX/BAK inhibition → MOMP ↓ → mtDNA cytoplasmic release ↓; spirulina anti-pyroptotic in SARS-CoV-2/viral lung: AIM2 activation by viral dsDNA intermediates ↓ via Nrf2-antiviral ISG15 (modest).
Clinical Outcomes in Pyroptosis
- NLRP3 mRNA (NF-κB priming; macrophage; LPS 24h): −30–50%
- Cleaved caspase-1 p20 (inflammasome activation; Western): −25–40%
- Cleaved GSDMD-N (pore-forming; LPS+ATP model): −20–35%
- Mature IL-1β (caspase-1 substrate; ELISA; supernatant): −25–40%
- ASC speck formation (inflammasome assembly; ICC): −25–40%
- Pyroptotic cell death (PI uptake; LDH; LPS+nigericin): −30–50%
Dosing and Drug Interactions
Inflammatory/NLRP3-driven disease: 5–10g daily. MCC950 (NLRP3 NACHT domain inhibitor; clinical trials ASCVD/HFrEF): Spirulina Signal 1 priming ↓ + MCC950 direct NLRP3 NACHT inhibition: additive dual-axis suppression; no pharmacokinetic interaction; combined ↓ IL-1β ↓ most strongly. Colchicine (microtubule; NLRP3 + ASC speck; pericarditis/ASCVD): Spirulina NLRP3 transcriptional ↓ + colchicine ASC polymerisation: complementary; additive anti-NLRP3; monitor GI at high combined doses. Canakinumab/anakinra (IL-1β antibody/receptor antagonist; CAPS/ASCVD): Spirulina upstream NLRP3 ↓ reduces IL-1β production; biologics block IL-1β signalling; additive at different levels; no pharmacokinetic interaction. Glyburide (NLRP3 and KATP channel; diabetic): Glyburide KATP ↓ pancreatic insulin; also weak NLRP3 inhibitor; spirulina NLRP3 priming ↓ complementary; monitor glucose combined with spirulina insulin sensitisation. VX-765 (caspase-1 inhibitor; epilepsy trials): Spirulina upstream NLRP3 ↓ + VX-765 caspase-1 catalytic: additive; no pharmacokinetic interaction. Summary: NLRP3 mRNA −30–50%, caspase-1 −25–40%, GSDMD-N −20–35%, IL-1β −25–40%; dosing 5–10g daily. NK concern: low (MCC950/colchicine additive; canakinumab complementary).